Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
NCT06681285
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Carcinoma
Interventions
DRUG:
Cadonilimab ;Anlotinib
Sponsor
Hebei Medical University Fourth Hospital